KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBIT (2016 - 2026)

Pacific Biosciences Of California has reported EBIT over the past 16 years, most recently at -$41.2 million for Q4 2025.

  • For Q4 2025, EBIT rose 73.08% year-over-year to -$41.2 million; the TTM value through Dec 2025 reached -$553.9 million, down 16.77%, while the annual FY2025 figure was -$553.9 million, 16.77% down from the prior year.
  • EBIT for Q4 2025 was -$41.2 million at Pacific Biosciences Of California, down from -$38.9 million in the prior quarter.
  • Over five years, EBIT peaked at -$33.7 million in Q1 2021 and troughed at -$428.9 million in Q1 2025.
  • A 5-year average of -$95.0 million and a median of -$74.6 million in 2022 define the central range for EBIT.
  • On a YoY basis, EBIT climbed as much as 74.49% in 2025 and fell as far as 427.19% in 2025.
  • Year by year, EBIT stood at -$64.7 million in 2021, then tumbled by 34.65% to -$87.1 million in 2022, then fell by 0.53% to -$87.5 million in 2023, then plummeted by 74.79% to -$153.0 million in 2024, then skyrocketed by 73.08% to -$41.2 million in 2025.
  • Business Quant data shows EBIT for PACB at -$41.2 million in Q4 2025, -$38.9 million in Q3 2025, and -$44.9 million in Q2 2025.